000136828 001__ 136828
000136828 005__ 20240229105101.0
000136828 0247_ $$2doi$$a10.1158/0008-5472.CAN-17-2900
000136828 0247_ $$2pmid$$apmid:29735552
000136828 0247_ $$2pmc$$apmc:PMC6065509
000136828 0247_ $$2ISSN$$a0008-5472
000136828 0247_ $$2ISSN$$a0099-7013
000136828 0247_ $$2ISSN$$a0099-7374
000136828 0247_ $$2ISSN$$a1538-7445
000136828 0247_ $$2altmetric$$aaltmetric:41165650
000136828 037__ $$aDKFZ-2018-01266
000136828 041__ $$aeng
000136828 082__ $$a610
000136828 1001_ $$aWang, Sophia S$$b0
000136828 245__ $$aHLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes.
000136828 260__ $$aPhiladelphia, Pa.$$bAACR$$c2018
000136828 3367_ $$2DRIVER$$aarticle
000136828 3367_ $$2DataCite$$aOutput Types/Journal article
000136828 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1536232510_3592
000136828 3367_ $$2BibTeX$$aARTICLE
000136828 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000136828 3367_ $$00$$2EndNote$$aJournal Article
000136828 520__ $$aA growing number of loci within the human leukocyte antigen (HLA) region have been implicated in non-Hodgkin lymphoma (NHL) etiology. Here, we test a complementary hypothesis of 'heterozygote advantage' regarding the role of HLA and NHL, whereby HLA diversity is beneficial and homozygous HLA loci are associated with increased disease risk. HLA alleles at class I and II loci were imputed from genome-wide association studies (GWAS) using SNP2HLA for 3,617 diffuse large B-cell lymphomas (DLBCL), 2,686 follicular lymphomas (FL), 2,878 chronic lymphocytic leukemia/small lymphocytic lymphomas (CLL/SLL), 741 marginal zone lymphomas (MZL), and 8,753 controls of European descent. Both DLBCL and MZL risk were elevated with homozygosity at class I HLA-B and -C loci (OR DLBCL = 1.31, 95% CI = 1.06-1.60; OR MZL = 1.45, 95% CI = 1.12-1.89) and class II HLA-DRB1 locus (OR DLBCL = 2.10, 95% CI = 1.24-3.55; OR MZL = 2.10, 95% CI = 0.99-4.45). Increased FL risk was observed with the overall increase in number of homozygous HLA class II loci (P trend < 0.0001, FDR = 0.0005). These results support a role for HLA zygosity in NHL etiology and suggests that distinct immune pathways may underly the etiology of the different NHL subtypes.Significance: HLA gene diversity reduces risk for non-Hodgkin lymphoma. Cancer Res; 78(14); 4086-96. ©2018 AACR.
000136828 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000136828 588__ $$aDataset connected to CrossRef, PubMed,
000136828 7001_ $$aCarrington, Mary$$b1
000136828 7001_ $$aBerndt, Sonja I$$b2
000136828 7001_ $$aSlager, Susan L$$b3
000136828 7001_ $$aBracci, Paige M$$b4
000136828 7001_ $$aVoutsinas, Jenna$$b5
000136828 7001_ $$aCerhan, James R$$b6
000136828 7001_ $$aSmedby, Karin E$$b7
000136828 7001_ $$aHjalgrim, Henrik$$b8
000136828 7001_ $$aVijai, Joseph$$b9
000136828 7001_ $$aMorton, Lindsay M$$b10
000136828 7001_ $$aVermeulen, Roel$$b11
000136828 7001_ $$aPaltiel, Ora$$b12
000136828 7001_ $$aVajdic, Claire M$$b13
000136828 7001_ $$aLinet, Martha S$$b14
000136828 7001_ $$aNieters, Alexandra$$b15
000136828 7001_ $$ade Sanjose, Silvia$$b16
000136828 7001_ $$aCozen, Wendy$$b17
000136828 7001_ $$aBrown, Elizabeth E$$b18
000136828 7001_ $$00000-0001-5550-3375$$aTurner, Jennifer$$b19
000136828 7001_ $$aSpinelli, John J$$b20
000136828 7001_ $$aZheng, Tongzhang$$b21
000136828 7001_ $$aBirmann, Brenda M$$b22
000136828 7001_ $$aFlowers, Christopher R$$b23
000136828 7001_ $$0P:(DE-He78)1573258b58c33f1922ca9719d0c8c4ab$$aBecker, Nikolaus$$b24$$udkfz
000136828 7001_ $$aHolly, Elizabeth A$$b25
000136828 7001_ $$aKane, Eleanor$$b26
000136828 7001_ $$aWeisenburger, Dennis$$b27
000136828 7001_ $$aMaynadie, Marc$$b28
000136828 7001_ $$aCocco, Pierluigi$$b29
000136828 7001_ $$aAlbanes, Demetrius$$b30
000136828 7001_ $$00000-0002-3834-1535$$aWeinstein, Stephanie J$$b31
000136828 7001_ $$aTeras, Lauren R$$b32
000136828 7001_ $$aDiver, W Ryan$$b33
000136828 7001_ $$aLax, Stephanie J$$b34
000136828 7001_ $$aTravis, Ruth C$$b35
000136828 7001_ $$0P:(DE-HGF)0$$aKaaks, Rudolph$$b36
000136828 7001_ $$aRiboli, Elio$$b37
000136828 7001_ $$aBenavente, Yolanda$$b38
000136828 7001_ $$aBrennan, Paul$$b39
000136828 7001_ $$aMcKay, James$$b40
000136828 7001_ $$aDelfau-Larue, Marie-Hélène$$b41
000136828 7001_ $$aLink, Brian K$$b42
000136828 7001_ $$aMagnani, Corrado$$b43
000136828 7001_ $$aEnnas, Maria Grazia$$b44
000136828 7001_ $$aLatte, Giancarlo$$b45
000136828 7001_ $$aFeldman, Andrew L$$b46
000136828 7001_ $$aDoo, Nicole Wong$$b47
000136828 7001_ $$aGiles, Graham G$$b48
000136828 7001_ $$aSouthey, Melissa C$$b49
000136828 7001_ $$aMilne, Roger L$$b50
000136828 7001_ $$aOffit, Kenneth$$b51
000136828 7001_ $$aMusinsky, Jacob$$b52
000136828 7001_ $$aArslan, Alan A$$b53
000136828 7001_ $$aPurdue, Mark P$$b54
000136828 7001_ $$aAdami, Hans-Olov$$b55
000136828 7001_ $$aMelbye, Mads$$b56
000136828 7001_ $$aGlimelius, Bengt$$b57
000136828 7001_ $$aConde, Lucia$$b58
000136828 7001_ $$aCamp, Nicola J$$b59
000136828 7001_ $$aGlenn, Martha$$b60
000136828 7001_ $$aCurtin, Karen$$b61
000136828 7001_ $$aClavel, Jacqueline$$b62
000136828 7001_ $$aMonnereau, Alain$$b63
000136828 7001_ $$aCox, David G$$b64
000136828 7001_ $$aGhesquières, Hervé$$b65
000136828 7001_ $$aSalles, Gilles$$b66
000136828 7001_ $$aBofetta, Paulo$$b67
000136828 7001_ $$aForetova, Lenka$$b68
000136828 7001_ $$aStaines, Anthony$$b69
000136828 7001_ $$aDavis, Scott$$b70
000136828 7001_ $$aSeverson, Richard K$$b71
000136828 7001_ $$aLan, Qing$$b72
000136828 7001_ $$aBrooks-Wilson, Angela$$b73
000136828 7001_ $$aSmith, Martyn T$$b74
000136828 7001_ $$aRoman, Eve$$b75
000136828 7001_ $$aKricker, Anne$$b76
000136828 7001_ $$aZhang, Yawei$$b77
000136828 7001_ $$aKraft, Peter$$b78
000136828 7001_ $$aChanock, Stephen J$$b79
000136828 7001_ $$aRothman, Nathaniel$$b80
000136828 7001_ $$aHartge, Patricia$$b81
000136828 7001_ $$aSkibola, Christine F$$b82
000136828 773__ $$0PERI:(DE-600)2036785-5$$a10.1158/0008-5472.CAN-17-2900$$gVol. 78, no. 14, p. 4086 - 4096$$n14$$p4086 - 4096$$tCancer research$$v78$$x1538-7445$$y2018
000136828 909CO $$ooai:inrepo02.dkfz.de:136828$$pVDB
000136828 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1573258b58c33f1922ca9719d0c8c4ab$$aDeutsches Krebsforschungszentrum$$b24$$kDKFZ
000136828 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b36$$kDKFZ
000136828 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000136828 9141_ $$y2018
000136828 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000136828 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER RES : 2015
000136828 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000136828 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000136828 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000136828 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000136828 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000136828 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000136828 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000136828 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000136828 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000136828 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000136828 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000136828 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCER RES : 2015
000136828 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x0
000136828 980__ $$ajournal
000136828 980__ $$aVDB
000136828 980__ $$aI:(DE-He78)C020-20160331
000136828 980__ $$aUNRESTRICTED